Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07439172 | Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma. | PHASE2 | NOT YET_RECRUITING | 70 | — | — | Mar 1, 2026 | Sep 1, 2029 | Feb 26, 2026 | - | — |
| Name | Type | Description |
|---|---|---|
| Pre-radiation temozolomide. | DRUG | Patients will receive 2 cycles of pre-radiation temozolomide (200mg/m\^2). Cycles are 28-days in length. Participants will take temozolomide on days 1-5 of the 28-day cycle. |